152 related articles for article (PubMed ID: 36571432)
1. Pharmacophore based virtual screening & molecular docking approach for identification of mycobacterial membrane protein large 3 (MmpL3) inhibitors.
Dhulap A; Banerjee P
J Biomol Struct Dyn; 2023 Dec; 41(20):11062-11077. PubMed ID: 36571432
[TBL] [Abstract][Full Text] [Related]
2. Computational design of MmpL3 inhibitors for tuberculosis therapy.
Chaitra R; Gandhi R; Jayanna N; Satyanath S; Pavadai P; Murahari M
Mol Divers; 2023 Feb; 27(1):357-369. PubMed ID: 35477825
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of anti-mycobacterial drug leads that target the mycolic acid transporter MmpL3.
Hu T; Yang X; Liu F; Sun S; Xiong Z; Liang J; Yang X; Wang H; Yang X; Guddat LW; Yang H; Rao Z; Zhang B
Structure; 2022 Oct; 30(10):1395-1402.e4. PubMed ID: 35981536
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations.
Saxena S; Abdullah M; Sriram D; Guruprasad L
J Biomol Struct Dyn; 2018 Sep; 36(12):3184-3198. PubMed ID: 28948866
[TBL] [Abstract][Full Text] [Related]
5. A piperidinol-containing molecule is active against
Dupont C; Chen Y; Xu Z; Roquet-Banères F; Blaise M; Witt AK; Dubar F; Biot C; Guérardel Y; Maurer FP; Chng SS; Kremer L
J Biol Chem; 2019 Nov; 294(46):17512-17523. PubMed ID: 31562241
[No Abstract] [Full Text] [Related]
6. Discovery of newer pyrazole derivatives with potential anti-tubercular activity via 3D-QSAR based pharmacophore modelling, virtual screening, molecular docking and molecular dynamics simulation studies.
Modi P; Patel S; Chhabria M
Mol Divers; 2023 Aug; 27(4):1547-1566. PubMed ID: 35969333
[TBL] [Abstract][Full Text] [Related]
7. Molecular Modelling and Atomistic Insights into the Binding Mechanism of MmpL3 Mtb.
Kwofie SK; Hanson G; Sasu H; Enninful KS; Mensah FA; Nortey RT; Yeboah OP; Agoni C; Wilson MD
Chem Biodivers; 2022 Sep; 19(9):e202200160. PubMed ID: 35969844
[TBL] [Abstract][Full Text] [Related]
8. Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target.
Zhang B; Li J; Yang X; Wu L; Zhang J; Yang Y; Zhao Y; Zhang L; Yang X; Yang X; Cheng X; Liu Z; Jiang B; Jiang H; Guddat LW; Yang H; Rao Z
Cell; 2019 Jan; 176(3):636-648.e13. PubMed ID: 30682372
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, antitubercular profile and molecular docking studies of quinazolinone-based pyridine derivatives against drug-resistant tuberculosis.
Raghu MS; Yogesh Kumar K; Shamala T; Alharti FA; Prashanth MK; Jeon BH
J Biomol Struct Dyn; 2024 Apr; 42(7):3307-3317. PubMed ID: 37261798
[TBL] [Abstract][Full Text] [Related]
10. Inhibitor binding studies of
Mallavarapu BD; Abdullah M; Saxena S; Guruprasad L
J Biomol Struct Dyn; 2019 Sep; 37(14):3751-3763. PubMed ID: 30239262
[TBL] [Abstract][Full Text] [Related]
11. A holistic molecular modelling approach to design novel indole-2-carboxamide derivatives as potential inhibitors of MmpL3.
Ray R; Das S; Lobo M; Birangal SR; Shenoy GG
SAR QSAR Environ Res; 2022 Jul; 33(7):551-581. PubMed ID: 35850557
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biological evaluation and docking studies of silicon incorporated diarylpyrroles as MmpL3 inhibitors: An effective strategy towards development of potent anti-tubercular agents.
Vasudevan N; Motiwala Z; Ramesh R; Wagh SB; Shingare RD; Katte R; Anand A; Choudhary S; Kumar A; Gokhale RS; Kulkarni KA; Reddy DS
Eur J Med Chem; 2023 Nov; 259():115633. PubMed ID: 37524010
[TBL] [Abstract][Full Text] [Related]
13. Structure-directed identification of pyridine-2-methylamine derivatives as MmpL3 inhibitors for use as antitubercular agents.
Wen Y; Lun S; Jiao Y; Zhang W; Liu T; Yang F; Tang J; Bishai WR; Yu LF
Eur J Med Chem; 2023 Jul; 255():115351. PubMed ID: 37116266
[TBL] [Abstract][Full Text] [Related]
14. Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance.
Williams JT; Haiderer ER; Coulson GB; Conner KN; Ellsworth E; Chen C; Alvarez-Cabrera N; Li W; Jackson M; Dick T; Abramovitch RB
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405862
[TBL] [Abstract][Full Text] [Related]
15. Structural Basis for the Inhibition of Mycobacterial MmpL3 by NITD-349 and SPIRO.
Yang X; Hu T; Yang X; Xu W; Yang H; Guddat LW; Zhang B; Rao Z
J Mol Biol; 2020 Jul; 432(16):4426-4434. PubMed ID: 32512002
[TBL] [Abstract][Full Text] [Related]
16. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
17. Novel Inhibitors to MmpL3 Transporter of
Choksi H; Carbone J; Paradis NJ; Bennett L; Bui-Linh C; Wu C
ACS Omega; 2024 Mar; 9(12):13782-13796. PubMed ID: 38559933
[TBL] [Abstract][Full Text] [Related]
18. Ligand-based pharmacophore modelling, virtual screening and docking studies to identify potential compounds against FtsZ of Mycobacterium tuberculosis.
Suresh M; Naicker K; Solanki J; Ezirim SA; Turcio R; Tochukwu IG; Lakhdari K; Attah EI
Indian J Tuberc; 2023 Oct; 70(4):430-444. PubMed ID: 37968049
[TBL] [Abstract][Full Text] [Related]
19. Identification of potential non-nucleoside MraY inhibitors for tuberculosis chemotherapy using structure-based virtual screening.
Pandey P; Chatterjee S; Berida T; Doerksen RJ; Roy S
J Biomol Struct Dyn; 2022 Jul; 40(11):4832-4849. PubMed ID: 33353500
[TBL] [Abstract][Full Text] [Related]
20. Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors.
McNeil MB; O'Malley T; Dennison D; Shelton CD; Sunde B; Parish T
mSphere; 2020 Oct; 5(5):. PubMed ID: 33055263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
